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BACKGROUND: HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast
cancer. The aim of this study was to characterise the pharmacokinetics (PKs) of HuHMFG1 using a population PK model.
METHOD: Data were derived from a phase I study of 26 patients receiving HuHMFG1 at doses ranging from 1 to 16mgkg
 1. Data
were analysed using NONMEM software and covariates were included. A limited sampling strategy (LSS) was developed using
training and a validation data set.
RESULTS: A linear two-compartment model was shown to be adequate to describe data. Covariate analysis indicated that weight was
not related to clearance. An LSS was successfully developed on the basis of the model, in which one sample is collected immediately
before the start of an infusion and the second is taken at the end of infusion.
CONCLUSION: A two-compartment population PK model successfully describes HuHMFG1 behaviour. The model suggests using a
fixed dose of HuHMFG1, which would simplify dosing. The model could be used to optimise dose level and dosing schedule if more
data on the correlation between exposure and efficacy become available from future studies. The derived LSS could optimise further
PK assessment of this antibody.
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Breast cancer accounts for B25% of malignancies that affect
women (Kumle, 2008). Metastatic breast cancer remains incurable
and there is a need for new active treatments in this setting.
HuHMFG1 is a recombinant DNA-derived humanised monoclonal
human milk fat globule-1 antibody that targets the immunodomi-
nant epitope of the MUC1 gene product (Pericleous et al, 2005).
It was engineered by grafting the complementary determining
regions of the parental murine antibody (HMFG1) into the
consensus framework of a human IgG1. Unlike the low expression
rate of antigens such as HER2 (20–25%), polymorphic epithelial
mucin or MUC1 expression is considered to be universal (490%)
in breast cancer, as well as in other common epithelial cancers
(Singh and Bandyopadhyay, 2007).
Monoclonal antibodies specific for tumour-associated antigens
can induce an immunological cellular attack on tumour cells by a
process known as antibody-dependent cell-mediated cytotoxicity
(ADCC). HuHMFG1 has been demonstrated to be a potent
mediator of ADCC by recruiting natural components of the body’s
immune system (Snijdewint et al, 2001) HuHMFG1 binds to the
extracellular MUC1 peptide sequence, PDTR. These sequences are
not exposed in normal cells because of full glycosylation, but
aberrant glycosylation in cancer cells exposes the epitope to the
antibody. Therefore, HuHMFG1 has the potential for targeted anti-
cancer therapy in a wide range of MUC1 overexpressing epithelial
tumours, including breast cancer. HuHMFG1 has entered a
randomised phase II study in first-line ERþ/HER2  metastatic
breast cancer in combination with letrozole therapy.
Population pharmacokinetic (PK) models help to define the
optimal schedule of drug administration and offer several benefits,
including accounting for inter-subject variability through an
assessment of covariates. This can improve the model and under-
standing of PK. Moreover, using a preferred model, a limited
sampling strategy (LSS) can be created to undertake Bayesian
estimation of individual PK parameters with the minimal number of
patient samples (Royer et al, 2009). We present the results of a
population PK model for HuHMFG1, together with a proposed LSS.
MATERIALS AND METHODS
Study design and patients
Data were derived from an open-label, non-randomised, dose-
escalation phase I study (Pegram et al, 2009). The phase I study
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saimed to determine the safety, tolerability, PK and anti-tumour
activity of HuHMFG1 monotherapy in patients with locally
advanced or metastatic breast cancer who had previously been
treated with up to three chemotherapeutic regimens, including
neoadjuvant and adjuvant therapy. The following doses were
studied: 1, 3, 9 and 16mgkg
 1. The study was conducted in
accordance with the principles of the Declaration of Helsinki, and
written informed consent was obtained from all patients before
any study-specific screening procedures were performed. All
patients had a PK assessment during their exposure to treatment
and for up to 6 months after discontinuation of treatment.
Drug administration and sampling
HuHMFG1 was administered as an intravenous infusion of
60–180min using a rate-controlled infusion pump. The drug
was dispensed into 250ml normal saline (0.9% sodium chloride)
infusion bags. The duration of infusion depended on the dose level:
60min infusion at 1–3mgkg
 1; 120min infusion at 9mgkg
 1;a n d
180min infusion at 16mgkg
 1. Sampling was performed depending
on the administered dose, as described in Table 1. At each time
point, an aliquot of blood (3.5ml) was collected from each patient
using the opposite arm to that used for administration of the drug.
Blood was collected in a serum separator II tube and immediately
centrifuged at 1200g (or 3000r.p.m.) for 5min at 41C. Equal
volumes of serum were transferred into two transfer tubes and
stored at  201C pending analysis.
Drug assay
HuHMFG1 concentration was determined in human serum
samples by means of an enzyme-linked immunosorbent assay in
microtitre plate format. Calibration was carried out by performing
a four-parameter fit (absorbance vs nominal concentration of
calibration samples, including ‘0’ standard). The calibration range
was 0–10.00mgl
 1. The lower limit of quantification for this assay
was determined to be 0.50mgl
 1. Samples with measured
concentration above the upper limit of quantification were re-
analysed at a higher dilution.
Population PK analysis
Pharmacokinetic data were analysed using the non-linear mixed
effects modelling approach as implemented in NONMEM software
version VI, level 1.0 (ICON Development Solutions, Ellicott City,
MD, USA; Beal et al, 1989–2006). First-order conditional estimation
with the INTERACTION option was used. Several models were
investigated: one-, two- or three-compartmental linear models, with
or without additional non-linear elimination. The choice between
models was made by evaluation of goodness-of-fit. This assessment
consisted of comparison of the following graphs: observed
concentrations vs predictions (OBS–PRED) and weighted residuals
vs predictions (WRES–PRED) using the R program.
Several models were investigated for residual variability: exponential,
additive or a combination of both error models. Inter-individual
variability was modelled with an exponential random effect.
The following covariates were investigated on V1 (central
volume of distribution) and CL (the clearance), but not on V2
(peripheral volume) or Q (inter-compartmental clearance), for
which no inter-subject variability could be isolated: age, body
weight, height, body mass index, serum albumin, serum total
protein concentration, creatinine clearance (Cockcroft and Gault,
1976), alkaline phosphatase (ALP), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), g-glutamyl transpepti-
dase (GGT), CA15–3 and CA27.29 antigens, and the presence of
liver metastasis. Human anti-human antibodies (HAHAs) were, at
the minimum, to be assessed in all patients, irrespective of dose.
Results of HAHA assessments were available from baseline and
4 weeks after start of therapy for 23 patients, and at 4 weeks after
treatment discontinuation for 17 patients out of 26 enrolled
patients. Between three and four HAHA assessment results were
available for the majority of patients. The HAHA antibodies were
not detected in the serum of any patients and thus not further
investigated. Covariates were selected in the final population
model if their effect was biologically plausible; if they produced a
minimum reduction of 4 in the objective function value; if they
produced a reduction in the variability of the PK parameter; and,
finally, if a minimum increase of 7 was observed after removal
from the final model.
Table 1 Sampling schedule of HuHMFG1
First administration (h)
Posology (mgkg
 1) Pre-dose EOI
a 1.5 4 6 12 24 48 72 144 168 216 240 312 336 648 672 840
1 | | | ||| | | | | |
3
a | | ||| | | | |
3
b | | | | | | | | ||| |
9 || | | | | | |
16 || | | | | | |
Following administrations
Posology (mgkg
 1) Pre-dose EOI Day 3 Day 5 Day 8
1 ||
3 || | | |
9 || | |
16 || | |
After the last administration
Posology (mgkg
 1) Day 3 Day 5 Day 7 Day 10 Day 20 Day 28 Week 10 Week 16 Week 22
1 || |
3 || | | | | | |
9 || | | |
16 || | | | |
Abbreviation: EOI¼end of infusion. The last administration was undertaken if no toxicity was observed.
aPerformed with three patients.
bPerformed with six patients.
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sThe accuracy and robustness of the final models were evaluated
by a bootstrap approach consisting of repeated random sampling
with replacement from the original data using Wings for
NONMEM (Holford et al, 1993a,b; Sheiner, 1997). Re-sampling
was performed 1000 times. Mean values and the precision of
parameters obtained by this procedure were compared with those
obtained with the original set. The final models were also evaluated
using a visual predictive check (VPC) assessment obtained after
1000 simulations of the data set. The percentage of observed data
outside the 5th and 95th percentiles of simulated concentrations
was calculated to assess the final models. Together with these
assessments, a normalised prediction distribution error (NPDE)
assessment (Brendel et al, 2006) was performed. A total of 1000
Monte Carlo simulations were performed to calculate NPDE using
an add-on package for R (Comets et al, 2008). The distribution of
the obtained NPDE was compared with a normalised distribution.
An LSS was built with the aim of decreasing the number of samples
required in further studies. The LSS was based on clearance
prediction and performed by splitting patient results into two groups
of 13 patients: one group for development of the LSS model and one
group for validation and assessment of the model. The accuracy of
the LSS model was assessed by computing the mean relative
prediction error (mpe%). Precision of the model was assessed by
the root mean squared relative prediction error (rmse%). These
parameters were calculated as follows, where N is the number of
patients and pej is the prediction error in the jth individual:
pej¼
ClLSS Cl
Cl
mpe% ¼ N 1  
X N
j¼1
ðpejÞ
rmse% ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N 1  
X N
j¼1
ðpejÞ
2
v u u t
The choice of times for the retained LSS was determined on the
basis of the values of mpe% and rmse% and the convenience of
sampling times.
RESULTS
Patient population
A total of 435 samples obtained from 26 patients were available
for population PK analysis. The demographic characteristics of
patients is summarised in Table 2. There were three, nine, six and
eight patients in the 1, 3, 9 and 16mgkg
 1 groups, respectively.
Data observed during the first administration are shown in
Figure 1. In all, 24 patients received a second administration, 23 a
third, 19 a fourth, 13 a fifth, 12 a sixth, 4 a seventh and 1 patient
received 10 administrations.
Population PK model
HuHMFG1 concentrations in the serum were best described by
a two-compartment linear model with a zero-order infusion
(ADVAN3 TRANS4 subroutine). The PK parameters calculated
with this model were clearance (CL), central volume of distribution
(V1), inter-compartmental clearance (Q) and peripheral volume of
distribution (V2) (Table 3). Inter-patient variability was described
by an exponential error model, whereas residual variability was
described by a combined proportional and fixed additive error
model. Inter-occasion variability was assessed with an exponential
random effect and was found to be insignificant. Random effects
could not be obtained for either Q or V2.
Among the tested covariates, ALP, GGT and AST lead to a
significant decrease in the objective function of central CL only.
Nonetheless, only AST was retained after the removal step, leading
to a 32.4% decrease in associated variability. The final model
including covariate is as follows, where ASTmed is the median value
of AST in the studied population:
CLðLh  1Þ¼0:016 þ 0:0036 
AST
ASTmed
     
Body weight was not found to be a covariate, indicating that fixed
dosing of HuHMFG1 may be a viable option.
The assessment of goodness-of-fit of predicted vs observed
HuHMFG1 concentrations and of weighted residuals vs predicted
serum concentration for the final model is shown in Figure 2A
and B. Bootstrap evaluation showed similar estimates compared
with the original PK parameters, as shown in Table 3. A median
distribution half-life of 1.87 (0.49–2.29) days and a terminal
elimination half-life of 11.04 (4.38–15.04) days were further
calculated from these parameters.
Assessment of the model
Evaluation of the model was undertaken using VPC assessment. The
results of the first four administrations are shown in Figure 3A–D. One
can observe that the limit of the 95th percentile could overestimate
concentrations during the first 4h after the first administration
Table 2 Demographic characteristics of covariates in the studied
population
Covariate Median (min max)
Age (years) 55 (32–72)
Weight (kg) 73.1 (50-108)
Height (cm) 165 (155–179)
Body mass index (kgm
 2) 25.75 (18.00–40.65)
Total protein concentration (gl
 1) 68 (54–82)
Albumin concentration (gl
 1) 41 (27–48)
Creatinine clearance (mlmin
 1) 85.3 (37.2–648.9)
Alkaline phosphatase (Unitsl
 1) 86 (47–1127)
Alanine aminotransferase (Unitsl
 1) 27 (6–252)
Aspartate aminotransferase (Unitsl
 1) 29 (14–1392)
g-Glutamyl transpeptidase (Unitsl
 1) 37 (9–1386)
CA15-3 45 (9–16400)
CA27.29 31.3 (3.5–1723)
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Figure 1 Semi-logarithmic representation of concentration–time pro-
files obtained from 26 patients during first administration of HuHMFG1.
Administered doses were 1mgkg
 1 (white triangle, solid line), 3mgkg
 1
(black square, solid line), 9mgkg
 1 (cross, dashed line) and 16mgkg
 1
(open circle, solid line).
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s(Figure 3A). This could be due to the fact that, during this period, data
include concentrations obtained from the end of infusion with high
doses (9 and 16mgkg
 1) and concentrations at the declining phase
after the end of infusion with low doses (1 and 3mgkg
 1)( T a b l e1 ) .
The combination of very high concentrations (e.g., from the end of
infusion samples after a 16mgkg
 1 dose) and very low concentrations
(e.g., from post-infusion samples after 1mgkg
 1 dose) could account
for the observed discrepancy. When samples of the same dose range
were separated at B48hforsamplesfromthe1and3mgkg
 1 cohorts,
or at B72h from the 9 and 16mgkg
 1 cohorts, the model described
the concentrations successfully. The same conclusion could be drawn
for the second, third and fourth administrations (Figure 3B–D). In
every case, the model successfully described the CL of patients.
Examination of the VPC figures and the WRES vs time graph for cycle
5–cycle 10 (data not shown) indicated that no bias appeared with time.
Hence, even if the number of patients and samples was lower
compared with that of previous cycles, on can draw similar conclusions
for the fifth and later cycles.
The model was further evaluated using the recently published
NPDE assessment (Brendel et al, 2006). According to this assessment,
when data are adequately described by the model, the calculated
NPDE (performed after 1000 simulations) should follow a normal
distribution. The distribution of NPDE obtained with the present
model does follow a normal distribution, as observed in the Q–Q
plot of Figure 4A and in the distribution graph of Figure 4B.
Limited sampling strategy
To facilitate PK studies and to decrease the number of blood samples
required for further studies, an LSS based on CL assessment was
developed. Eight strategies were assessed with 1, 2 or 3 samples.
Results obtained with these strategies using the training group are
presented in Table 4. Taking into account accuracy (mpe%),
precision (rmse%), number of samples and convenience of sampling,
the LSS consisting of samples collected before and after infusion was
retained. With this LSS, the validation group led to a similar mpe%
of  1.41% and rmse% of 6.60%. Performing this LSS with all
patients led to an mpe% of 3.23% and an rmse% of 7.74%. A
correlation was also observed between actual CL values and
predicted CL values, with a slope of 1.00 and an r
2 of 0.913.
DISCUSSION AND CONCLUSION
This study establishes a population PK model for HuHMFG1, a
recombinant DNA-derived humanised monoclonal antibody that
targets the MUC1 gene product. The selected model is a two-
compartmental model with linear elimination, and was shown to
successfully describe the data using bootstrap, VPC and NPDE
assessments. Other models tested (one- or three-compartmental
models) with non-linear or combined (linear and non-linear)
elimination were more complex and did not lead to improved
results. The absence of the production of HAHA by patients may
strengthen this observation. Indeed, these auto-antibodies are
likely to modify the clearance of therapeutic antibodies (Limsakun,
2006; Saito-Yabe et al, 2009). The absence of such phenomenon
leads to PK parameters similar to endogenous IgG and other
antibodies for which no HAHA response has been detected.
Indeed, a structural two-compartmental model is commonly
reported to describe the behaviour of antibodies. In these models,
the associated elimination is mainly linear (Kovarik et al, 2001;
Bruno et al, 2005; Ng et al, 2006; Dartois et al, 2007) and less
frequently non-linear (Mould et al, 1999, 2007). Rarely does a
combined linear and non-linear process describe the elimination
of antibodies (Kuester et al, 2008).
Table 3 Population pharmacokinetic parameters of HuHMFG1 and
bootstrap evaluation
Final model original data Bootstrap evaluation
Parameter Mean s.d. Mean s.d.
V1 (l)
y 3.31 0.14 3.29 0.13
o
2 0.042 0.010 0.040 0.010
CL (lh
 1)
y 0.016 0.002 0.016 0.002
o
2 0.062 0.018 0.059 0.020
Q( lh
 1)
y 0.017 0.004 0.018 0.004
o
2 NA NA NA NA
V2 (l)
y 2.33 0.42 2.32 0.37
o
2 NA NA NA NA
COVCL
y 0.0036 0.0012 0.0035 0.0012
s1
2 (proportional)
y 0.034 0.004 0.033 0.004
s2
2 (additive) (mgl
 1)
y 2.26 (fixed) NA 2.26 (fixed) NA
Abbreviations: V1¼volume of the central compartment; V2¼peripheral volume;
Q¼inter-compartmental clearance; y¼value of the corresponding parameter;
o
2¼value of the inter-subject variability associated with the corresponding
parameter; COVCL¼value of the parameter associated with the equation of the
covariate; s1
2: proportional part of the residual error; s2
2¼additive part of the residual
error; NA¼not assessable.
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Figure 2 Goodness-of-fit obtained with the model objectified through
observed concentrations vs (A) predicted (PRED) observations and
through (B) weighted residuals (WRES) vs predicted (PRED) observations.
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sValues of the final parameters were similar to those reported for
other antibodies, with regard to CL from the central compartment
and Q, V1 and V2 (Kovarik et al, 2001; Bruno et al, 2005; Ng et al,
2006; Dartois et al, 2007; Mould et al, 2007; Kuester et al, 2008; Lu
et al, 2008). This indicates that the HuHMFG1 antibody, similar to
other therapeutic antibodies, is mainly distributed in the serum.
Covariate analysis indicated that, despite a weight-based
administration in the phase I study, weight was not related to V1
or CL. This indicates that CL seems to remain stable independently
of the patient’s weight. A similar conclusion was drawn by Ng et al
(2006) who observed that weight and body surface area were
significant covariates, but had a weak impact on patient sample
concentrations. Therefore, one could consider recommending a
fixed-dose instead of a weight-based dosing regimen for
HuHMFG1. Future clinical studies will be necessary to define the
optimal dosing regimen.
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Figure 3 Accuracy of the final model evaluated by posterior visual predictive check assessment obtained after 1000 simulations. (A–D, respectively)
Data correspond to the first four administrations, which are representative of further administrations. Solid lines correspond to 5th and 95th percentiles;
dashed line corresponds to the median.
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Figure 4 (A) Q–Q plot of the NPDE obtained after 1000 Monte Carlo
simulations of the model. The solid line represents the identity line. (B)
Shows the frequency distribution of the NPDE (histograms) compared with
the theoretical normal distribution (solid line).
Table 4 Accuracy (mpe%) and precision (rmse%) of LSSs tested
No. of samples Sampling time (h) mpe% rmse%
1T C  5.53 10.73
2 TC, EOI  5.68 8.59
2T C , 4 5.82 10.60
2T C , 6 5.15 10.75
2T C , 2 4  5.24 10.02
3 TC, EOI, 4  5.58 8.45
3 TC, EOI, 6  5.45 8.66
8–12 Cycle 1  9.81 18.68
Abbreviations: mpe%¼mean relative prediction error; rmse%¼root mean squared
relative prediction error; LSS¼limited sampling strategy; TC¼trough concentration;
EOI¼end of infusion. The retained LSS is indicated in italics.
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sInterestingly, the hepatic enzyme AST was found to be
significantly related to clearance of HuHMFG1. In contrast, in cases
in which hepatic enzymes have been investigated as covariates in
population PK modelling for other antibodies, they were found not
to be significantly relevant (Kuester et al,2 0 0 8 ;L uet al,2 0 0 8 ;
Newsome and Ernstoff, 2008). Alanine aminotransferase has been
found to be strongly linked to another covariate and then eliminated
during the removal step of covariate study for trastuzumab (Bruno
et al, 2005), and ALP was found to be significantly linked to the
clearance of pertuzumab (Ng et al, 2006). In this study, when only
AST was retained during the removal step, ALP and GGT were also
found to be linked to the clearance of HuHMFG1 during the first step
of covariate study. This is related to the fact that hepatic enzymes
were generally elevated together. Retaining only AST during the
removal step suggests that AST level alone could partly explain the
variability of CL related to hepatic enzymes. Lu et al (2008) also
observed that AST could be linked to bevacizumab clearance, but
found it unlikely that impaired hepatic enzymes would actually alter
clearance. Moreover, some authors eliminate covariates because their
importance was driven by few patients and simulations showed weak
impact on PK parameters (Kuester et al, 2008). In our study, the link
between AST and clearance was based on data from a significant
number of patients, and simulations confirmed the impact of this
covariate on HuHMFG1 clearance. We choose to leave AST as a
covariate to ensure future investigation into a potentially relevant
finding, even if we cannot exclude the fact that the link is due to
random chance, as the physiological implication of liver metabolism
in IgG clearance is not obvious. A similar strategy was chosen by Ng
et al (2006), which considered ALP as the covariate of pertuzumab
clearance. Data obtained from further studies with HuHMFG1 are
required to confirm whether AST is indeed a covariate.
Using population PK parameters, an LSS was developed to
facilitate PK sampling and analysis for possible future studies. The
retained strategy included both pre- and post-infusion times. In
addition, considering the relatively small value of the proportional
part of the residual error (18.4%) and the fixed value of the
additive part of this error (2.26mgl
 1), the selected model
presents a reasonably high predictability. Thus, by using Bayesian
estimation, the retained LSS was shown to be a powerful tool for
assessing the CL of patients with a limited number of samples.
In conclusion, serum concentrations of HuHMFG1 can be
successfully described using a two-compartmental model with linear
elimination. Pharmacokinetic parameters indicate that the behaviour
of this antibody is similar to that of other therapeutic antibodies,
especially with regard to a central compartment represented by the
serum volume. Interestingly, patient weight was not linked to
clearance or central volume of distribution, indicating that a fixed
dose might be considered instead of a weight-based dosage, which
has been used in the phase II trial with HuHMFG1 in breast cancer.
The model presented here offers reasonably high predictability,
which, when combined with LSS, could help to guide further PK and
pharmacodynamic studies with HuHMFG1. If more data become
available linking exposure and efficacy of HuHMFG1, this model
would facilitate optimisation of the dose level and dosing schedule.
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